In summary, our results suggest that co-expression of two, three or all four HER-family members and CD44 overexpression are common in patients with Stages III and IV ovarian cancers and that EGFR and CD44 expression at different cut off values may be of prognostic value. This evidence concerns the gene CD44 and ovarian carcinoma.